Location: Special Hospital Medico (Rijeka)
Study Drug: Within the study, patients will receive either the already registered drug sunitinib or a combination of the registered drug nivolumab and an experimental drug from the group of tyrosine kinase inhibitors.
Main Inclusion Criteria: Patients with locally advanced, inoperable, or metastatic non-clear cell kidney cancer who have not been treated with systemic oncological therapy. Patients who have undergone surgery and experienced a recurrence of the disease may have previously received systemic oncological therapy (adjuvant).
Status: Enrolling patients
Start of patient enrollment: March 2024.
Planned completion of new patient enrollment: March 2025.
